Highview Capital Management LLC DE Boosts Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Highview Capital Management LLC DE boosted its stake in Boston Scientific Co. (NYSE:BSX) by 6.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,507 shares of the medical equipment provider’s stock after purchasing an additional 1,439 shares during the quarter. Highview Capital Management LLC DE’s holdings in Boston Scientific were worth $2,189,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Creative Planning boosted its stake in Boston Scientific by 7.7% during the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock valued at $17,113,000 after buying an additional 14,663 shares during the last quarter. Global Retirement Partners LLC boosted its position in shares of Boston Scientific by 11.5% during the 3rd quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider’s stock valued at $366,000 after acquiring an additional 449 shares during the last quarter. Stratos Wealth Advisors LLC boosted its position in shares of Boston Scientific by 8.9% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider’s stock valued at $538,000 after acquiring an additional 522 shares during the last quarter. Net Worth Advisory Group purchased a new position in shares of Boston Scientific in the third quarter valued at $373,000. Finally, Moss Adams Wealth Advisors LLC purchased a new stake in Boston Scientific during the third quarter valued at $256,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $106.20 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52 week low of $65.33 and a 52 week high of $107.17. The business’s 50 day moving average price is $96.44 and its 200 day moving average price is $88.29. The firm has a market cap of $156.51 billion, a P/E ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. On average, sell-side analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank of Canada boosted their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Thursday, February 6th. Wells Fargo & Company raised their price target on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Canaccord Genuity Group boosted their price target on Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a report on Monday, December 9th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $107.39.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares of the company’s stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 87,326 shares of company stock worth $8,673,948 over the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.